Smith & Nephew’s (SNN) “Hold” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group restated their hold rating on shares of Smith & Nephew (NYSE:SNN) in a report issued on Monday,Benzinga reports. They currently have a $27.00 target price on the medical equipment provider’s stock.

Other equities analysts have also issued research reports about the company. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. UBS Group cut shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Smith & Nephew currently has a consensus rating of “Hold” and a consensus target price of $27.00.

Smith & Nephew Price Performance

Shares of NYSE:SNN opened at $28.37 on Monday. The company has a market capitalization of $12.40 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock has a fifty day moving average of $26.60 and a 200-day moving average of $27.10. Smith & Nephew has a one year low of $23.65 and a one year high of $31.72.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be given a dividend of $0.447 per share. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a yield of 2.5%. Smith & Nephew’s dividend payout ratio (DPR) is presently 41.20%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Principal Securities Inc. raised its position in Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 691 shares in the last quarter. R Squared Ltd bought a new stake in shares of Smith & Nephew during the 4th quarter worth $41,000. National Bank of Canada FI boosted its holdings in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 446 shares during the period. Hara Capital LLC raised its stake in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 1,957 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Smith & Nephew by 31.8% during the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 718 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.